
Misako Nagasaka/X
Jun 13, 2025, 07:19
Misako Nagasaka Shares FDA Approval of Taletrectinib for ROS1-Positive NSCLC
Misako Nagasaka, Thoracic Oncologist at University of California Irvine, posted on X:
“Another option for patients!!
On June 11, 2025, the FDA approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive NSCLC.”
More posts featuring NSCLC.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 13, 2025, 07:19
Jun 13, 2025, 07:11
Jun 13, 2025, 06:53
Jun 13, 2025, 06:48
Jun 13, 2025, 06:27